

## 内科学第二

### 論文

#### A 欧文

A-a

- 1 . Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, Ichihashi G, Sanaki T, Baba K, Tsuge Y, Uehara T: Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study. *Clin Infect Dis* 76(8): 1403-1411,2023.doi: 10.1093/cid/ciac933. (IF: 11.8) \*
- 2 . Tokito T, Sakamoto N, Ishimoto H, Okuno D, Miyamura T, Hara A, Kido T, Yamamoto K, Yamaguchi H, Obase Y, Akazawa Y, Okamura K, Suzuki T, IshimatsuY, Mukae H: Pulmonary and Intestinal Involvement in a Patient with Myeloperoxidase-specific Antineutrophil Cytoplasmic Antibody-positive Hermansky-Pudlak Syndrome. *Intern Med* 62(1): 103-106,2023.doi: 10.2169/internalmedicine.9350-22. (IF: 1.27) \*
- 3 . Moriyama S, Kido T, Sakamoto N, Fuchigami M, Tokito T, Okuno D, Miyamura T, Nakashima S, Hara A, Ishimoto H, Imaizumi Y, Tsuruda K, Yanagihara K, Fukuoka J, Mukae H: Pulmonary Nodular Lymphoid Hyperplasia Evaluated with Bronchoalveolar Lavage Fluid Findings: A Case Report and Review of the Literature on Japanese Patients. *Intern Med* 62(1): 95-102,2023.doi: 10.2169/internalmedicine.9310-21.. (IF: 1.2) \*
- 4 . Mori M, Kido T, Sakamoto N, Ozasa M, Kido K, Noguchi Y, Tokito T, Okuno D, Yura H, Hara A, Ishimoto H, Suematsu T, Obase Y, Tanaka Y, Izumikawa K, Takeuchi K, Mukae H: Novel SPEF2 Variant in a Japanese Patient with Primary Ciliary Dyskinesia: A Case Report and Literature Review. *J Clin Med* 12(1): 317-317,2023.doi: 10.3390/jcm12010317. (IF: 4.964) \*
- 5 . Taniguchi H, Akagi K, Dotsu Y, Yamada T, Ono S, Imamura E, Gyotoku H, Takemoto S, Yamaguchi H, Sen T, Yano S, Mukae H: Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer. *Cancer Sci* 114(1): 164-173,2023.doi: 10.1111/cas.15579. (IF: 6.518) \*
- 6 . Kohno S, Izumikawa K, Takazono T, Miyazaki T, Yoshida M, Kamei K, Ogawa K, Taniguchi S, Akashi K, Tateda K, Mukae H, Miyazaki Y, Okada F, Kanda Y, Kakeya H, Suzuki J, Kimura SI, Kishida M, Matsuda M, Niki Y: Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. *J Infect Chemother* 29(2): 163-170,2023.doi: 10.1016/j.jiac.2022.10.010.. (IF: 2.2) \*
- 7 . Torigoe M, Obata Y, Inoue H, Torigoe K, Kinoshita A, Koji T, Mukae H, Nishino T: Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling. *Clin Exp Nephrol* 27(2): 110-121,2023.doi: 10.1007/s10157-022-02285-y. (IF: 2.3) \*
- 8 . Kaku N, Urabe T, Iida T, Yun C, Nishida Y, Onitsuka Y, Hashiguchi K, Hirose K, Tomonaga A, Izumikawa K, Mukae H, Yanagihara K: Gargle sample is an effective option in a novel fully automated molecular point-of-care test for influenza: a multicenter study. *Virol J* 20(1): 41,2023.doi: 10.1186/s12985-023-01993-5. (IF: 4.8) \*
- 9 . Akagi K, Yagishita S, Ohuchi M, Hayashi Y, Takeyasu Y, Masuda K, Shinno Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Mukae H, Ohe Y, Hamada A: Impact of ramucirumab pharmacokinetics in combination with docetaxel on the efficacy and survival in patients with advanced non-small cell lung cancer.. *Lung Cancer* 178: 247-253,2023.doi: 10.1016/j.lungcan.2023.03.001. (IF: 6.081) \*
- 10 . Ishimoto H, Sakamoto N, Ozasa M, Katoh T, Itonaga H, Wataya M, Takao D, Hara A, Kido T, Yamaguchi H, Yamamoto K, Obase Y, Ishimatsu Y, Miyazaki Y, Mukae H: A case of pulmonary Langerhans cell histiocytosis that progressed from single-system to multisystem form despite smoking cessation: A case report. *Intern Med* 62(6): 877-880,2023.doi: 10.2169/internalmedicine.0139-22. (IF: 1.2) \*
- 11 . Zaizen Y, Okamoto M, Azuma K, Fukuoka J, Hozumi H, Sakamoto N, Suda T, Mukae H, Hoshino T: Enhanced immune complex formation in the lungs of patients with dermatomyositis. *Respir Res* 24(1): 86,2023.doi: 10.1186/s12931-023-02362-0. (IF: 7.162) \*
- 12 . Takao R, Ito Y, Tanaka Y, Ashizawa N, Takeda K, Ide S, Iwanaga N, Tashiro M, Takazono T, Tanaka T, Sekino M, Furumoto A, Okano S, Hara T, Izumikawa K, Yanagihara K, Mukae H: A case of Strongyloides hyperinfection syndrome with elevated IgG4. *IDCases* 32: e01739,2023.doi: 10.1016/j.idcr.2023.e01739. (IF: 1.5) \*

- 13 . Umeyama Y, Taniguchi H, Gyotoku H, Senju H, Tomono H, Takemoto S, Yamaguchi H, Tagod MSO, Iwasaki M, Tanaka Y, Mukae H: Three distinct mechanisms underlying human  $\gamma\delta$  T cell-mediated cytotoxicity against malignant pleural mesothelioma. *Front Immunol.* 14: 1058838,2023.doi: 10.3389/fimmu.2023.1058838.. (IF: 8.787) ○\*
- 14 . Kikuchi S, Kosai K, Ota K, Mitsumoto-Kaseida F, Sakamoto K, Hasegawa H, Izumikawa K, Mukae H, Yanagihara K: Clinical and microbiological characteristics of bloodstream infection caused by *Klebsiella pneumoniae* harboring rmpA in Japanese adults. *Sci Rep* 13(1): 6571,2023.doi: 10.1038/s41598-023-33265-1. (IF: 4.6) \*
- 15 . Hirayama T, Miyazaki T, Sumiyoshi M, Ito Y, Ashizawa N, Takeda K, Iwanaga N, Takazono T, Yamamoto K, Izumikawa K, Yanagihara K, Makimura K, Tsukamoto K, Kohno S, Mukae H: Echinocandin Resistance in *Candida auris* Occurs in the Murine Gastrointestinal Tract Due to FKS1 Mutations. *Antimicrob Agents Chemother* 67(4): e0124322,2023.doi: 10.1128/aac.01243-22. (IF: 5.938) ★\*
- 16 . Setoguchi D, Iwanaga N, Ito Y, Ashizawa N, Hirayama T, Takeda K, Ide S, Takemoto S, Tashiro M, Hosogaya N, Takazono T, Sakamoto N, Obase Y, Izumikawa K, Yanagihara K, Mukae H: Pulmonary phaeohyphomycosis due to *Exophiala dermatitidis* in a patient with pulmonary non-tuberculous mycobacterial infection. *J Infect Chemother* : 2023.doi: 10.1016/j.jiac.2023.03.010. (IF: 2.065) \*
- 17 . Tamaki A, Kitamura M, Yamaguchi K, Notomi S, Tomura H, Sawase K, Hashiguchi J, Harada T, Funakoshi S, Takazono T, Mukae H, Nishino T: Poor prognosis after lower-limb amputation irrespective of diabetes status in patients undergoing hemodialysis. *Ther Apher Dial* 27(3): 495-504,2023.doi: 10.1111/1744-9987.13947. (IF: 1.9) \*
- 18 . Hirano K, Tashiro M, Takazono T, Miura T, Kohno Y, Kondo A, Sawai T, Hashiguchi K, Fukushima K, Inoue Y, Suyama N, Izumikawa K, Sato I, Yanagihara K, Mukae H, Kohno S, and Izumikawa K: Comparison of rapid immunochromatographic assays using sputum and urine for *Streptococcus pneumoniae* detection in adult patients with respiratory tract infection. *Acta Medica Nagasakiensia* 66: 71-79,2023.-. (IF: -)
- 19 . Umeyama Y, Taniguchi H, Yamaguchi H, Shimada M, Sugasaki N, Kinoshita A, Hayashi T, Abe K, Ono S, Gyotoku H, Senju H, Ikeda T, Katsumi N, Fukuda M, Takemoto S, Mukae H: Severe esophagitis directly induced by accumulation of crizotinib-residue at the esophageal mucosa proven with polarizing microscope examination. *ACTA MEDICA NAGASAKIENSIA* 66(2): 99-103,2023.-. (IF: -)
- 20 . Tagawa R, Soda H, Dotsu Y, Senju H, Irifune S, Yoshida M, Nakashima S, Umemura A, Iwasaki K, Taniguchi H, Takemoto S, Fukuda Y, Mukae H: Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia-inducible factor-1  $\alpha$ , vascular endothelial growth factor, and hypervascularization. *Thorac Cancer* 14(14): 1320-1324,2023.doi: 10.1111/1759-7714.14869. (IF: 2.9) \*
- 21 . Shimada M, Taniguchi H, Yamaguchi H, Gyotoku H, Sasaki D, Kaku N, Senju C, Senju H, Imamura E, Takemoto S, Yamamoto K, Sakamoto N, Obase Y, Tsuchiya T, Fukuda M, Soda H, Ashizawa K, Fukuoka J, Nagayasu T, Yanagihara K, Mukae H: Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets. *Transl Lung Cancer Res* 12(4): 707-718,2023.doi: 10.21037/tlcr-22-794. (IF: 4.726) ○\*
- 22 . Tashiro M, Sato S, Endo A, Hamashima R, Ito Y, Ashizawa N, Takeda K, Iwanaga N, Ide S, Fujita A, Takazono T, Yamamoto K, Tanaka T, Furumoto A, Yanagihara K, Mukae H, Fushimi K, Izumikawa K: Decreased community-acquired pneumonia coincided with rising awareness of precautions before governmental containment policy in Japan. *PNAS Nexus* 2(5): pgad153,2023.-. (IF: -)
- 23 . Kiyohara M, Miyazaki T, Okamoto M, Hirayama T, Makimura K, Chibana H, Nakada N, Ito Y, Sumiyoshi M, Ashizawa N, Takeda K, Iwanaga N, Takazono T, Izumikawa K, Yanagihara K, Kohno S, Mukae H: Evaluation of a Novel FKS1 R1354H Mutation Associated with Caspofungin Resistance in *Candida auris* Using the CRISPR-Cas9 System. *J Fungi* 9(5): 529,2023.doi: 10.3390/jof9050529. (IF: 5.724) ○★\*
- 24 . Tokito T, Kido T, Muramatsu K, Tokutsu K, Okuno D, Yura H, Takemoto S, Ishimoto H, Takazono T, Sakamoto N, Obase Y, Ishimatsu Y, Fujino Y, Yatera K, Fushimi K, Matsuda S, Mukae H: Impact of Administering Intravenous Azithromycin within 7 Days of Hospitalization for Influenza Virus Pneumonia: A Propensity Score Analysis Using a Nationwide Administrative Database. *Virusses* 15(5): 1142,2023.doi: 10.3390/v15051142.. (IF: 4.7) \*
- 25 . Morio R, Takazono T, Kubo R, Fukushima K, Suyama N, Izumikawa T, Izumikawa K, Yanagihara K, Mukae H: Survey of Advance Care Planning Practices in Elderly COVID-19 Patients: A Multicenter Questionnaire Survey. *Cureus* 15(5): 2023.doi: 10.7759/cureus.39663.. (IF: -)

- 26 . Torigoe K, Sakamoto R, Abe S, Muta K, Mukae H, Nishino T: Factors Associated with Glomerular Yield in Percutaneous Kidney Biopsy. *J Clin Med* 12(12): 3877,2023.doi: 10.3390/jcm12123877. (IF: 4.964) \*
- 27 . Takemoto S, Ozasa M, Mizuta R, Tagawa R, Ono S, Honda N, Suyama T, Umeyama Y, Dotsu Y, Gyotoku H, Yamaguchi H, Yamamoto K, Sakamoto N, Obase Y, Fukuda M, Mukae H: Proportion of biopsy specimens containing a tumor when compared to all biopsy specimens by transbronchial biopsy. *Lung Cancer Management* 11(4): LMT57,2023.doi: 10.2217/lmt-2022-0001.. (IF: 2.8) \*
- 28 . Ozasa M, Bychkov A, Zaizen Y, Tabata K, Uegami W, Yamano Y, Kataoka K, Johkoh T, Mukae H, Kondoh Y, Fukuoka J: Effect of the 2020 hypersensitivity pneumonitis guideline on the pathologic diagnosis of interstitial pneumonia.. : 2023.doi: 0.1038/s41598-023-35986-9. (IF: 4.6) \*
- 29 . Hanada M, Ishimatsu Y, Sakamoto N, Akiyama Y, Kido T, Ishimoto H, Oikawa M, Nagura H, Takeuchi R, Sato S, Takahata H, Mukae H, Kozu R: Urinary titin N-fragment as a predictor of decreased skeletal muscle mass in patients with interstitial lung diseases. *Sci Rep* 13(1): 9723,2023.doi: 10.1038/s41598-023-36827-5. (IF: 4.6) \*
- 30 . Takao D, Takeda K, Takazono T, Ozasa M, Ito Y, Ashizawa N, Hirayama T, Iwanaga N, Takemoto S, Ide S, Tashiro M, Hosogaya N, Kido T, Sakamoto N, Obase Y, Okano S, Izumikawa K, Yanagihara K, Mukae H: A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension. *J Infect Chemother* 29(8): 806-808,2023.doi: 10.1016/j.jiac.2023.04.013. (IF: 2.065) \*
- 31 . Murata M, Kosai K, Akamatsu N, Matsuyama Y, Oda M, Wakamatsu A, Izumikawa K, Mukae H, Yanagihara K: Diagnostic Performance of BD Phoenix CPO Detect Panels for Detection and Classification of Carbapenemase-Producing Gram-Negative Bacteria. . *Microbiol Spectr* 11(3): e0431122,2023.doi: 10.1128/spectrum. (IF: 3.7) \*
- 32 . Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasaji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S: A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. *Microbiol Spectr* 11(3): e431122,2023.doi: 10.1128/spectrum.04311-22 . (IF: 3.7) \*
- 33 . Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasaji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S: A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19. *Microbiol Spectr* 11(3): e0431122,2023.doi: 10.1128/spectrum.04311-22. (IF: 3.7) \*
- 34 . Hosogaya N, Takazono T, Kurazono K, Hiroi S, Iwasaki K, Takeshima T, Ha C, Mukae H: Estimation of Intangible Costs for Factors Associated with Oral Antiviral Drugs for COVID-19 Treatment: A Conjoint Analysis in Japan. *Adv Ther* : 2023.doi: 10.1007/s12325-023-02564-4. (IF: 3.8) \*
- 35 . Chojin Y, Okamoto N, Noguchi S, Fube Y, Aritake Y, Shiraki M, Izumitani K, Suzuki M, Omori M, Kato T, Mukae H, Yatera K: Clinical efficacy of assessment of swallowing ability for pneumonia and other assessment tools for occurrence and mortality from pneumonia among older inpatients in a long-term care hospital. *Respir Investig* 61(5): 651-659,2023.doi: 10.1016/j.resinv.2023.06.008. (IF: 3.1) \*
- 36 . Ito G, Takazono T, Hosogaya N, Iwanaga N, Miyazawa S, Fujita S, Watanabe H, Mukae H: Impact of meteorological and demographic factors on the influenza epidemic in Japan: a large observational database study. *Sci Rep* 13(1): 13000,2023.doi: 10.1038/s41598-023-39617-1.. (IF: 4.6) \*
- 37 . Koga S, Takazono T, Kido T, Muramatsu K, Tokutsu K, Tokito T, Okuno D, Ito Y, Yura H, Takeda K, Iwanaga N, Ishimoto H, Sakamoto N, Yatera K, Izumikawa K, Yanagihara K, Fujino Y, Fushimi K, Matsuda S, Mukae H: Evaluation of the Effectiveness and Use of Anti-Methicillin-Resistant Staphylococcus aureus Agents for Aspiration Pneumonia in Older Patients Using a Nationwide Japanese Administrative Database. *Microorganisms* 11(8): 1905,2023.doi: 10.3390/microorganisms11081905.. (IF: 4.5) \*

- 38 . Tanaka T, Tashiro M, Ota K, Fujita A, Sawai T, Kadota J, Fukuda Y, Sumiyoshi M, Ide S, Tachikawa N, Fujii H, Hibino M, Shiomi H, Izumida M, Matsui K, Yamauchi M, Takahashi K, Yamanashi H, Sugimoto T, Akabame S, Umeda M, Shimizu M, Hosogaya N, Kosai K, Takeda K, Iwanaga N, Ashizawa N, Hirayama T, Takazono T, Yamamoto K, Imamura Y, Miyazaki T, Kobayashi Y, Ariyoshi K, Mukae H, Yanagihara K, Kita K, Izumikawa K: Safety and efficacy of 5-aminolevulinic acid phosphate/iron in mild-to-moderate coronavirus disease 2019: A randomized exploratory phase II trial. *Medicine (Baltimore)* 102(34): e34858,2023.doi: 10.1097/MD.00000000000034858. (IF: 1.6) \*
- 39 . Takazono T, Ngwe Tun MM, Funakoshi S, Morimoto S, Ota K, Torigoe K, Abe S, Muta K, Ito Y, Ashizawa N, Kitamura M, Takeda K, Iwanaga N, Ide S, Tashiro M, Hosogaya N, Nishino T, Yanagihara K, Izumikawa K, Morita K, Mukae H: Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients. *Kidney Int Rep* 8(9): 1883-1886,2023.doi: 10.1016/j.kir.2023.06.008.. (IF: 6) \*
- 40 . Yamaguchi K, Kitamura M, Otsuka E, Notomi S, Funakoshi S, Mukae H, Nishino T: Association between annual variability of potassium levels and prognosis in patients undergoing hemodialysis. *Clin Exp Nephrol* 27(10): 873-881,2023.doi: 10.1007/s10157-023-02368-4. Epub 2023. (IF: 2.3) \*
- 41 . Nakada N, Miyazaki T, Mizuta S, Hirayama T, Nakamichi S, Takeda K, Mukae H, Kohno S, Tanaka Y: Screening and synthesis of tetrazole derivatives that inhibit the growth of cryptococcus species . *ChemMedChem* 18(18): 651-659,2023.doi: 10.1002/cmdc.202300157. (IF: 3.4) \*
- 42 . Ashizawa H, Iwanaga N, Kurohama H, Ito Y, Ashizawa N, Hirayama T, Takeda K, Ide S, Nagayoshi Y, Tashiro M, Takazono T, Tagawa T, Fukushima K, Ito M, Nakamura S, Izumikawa K, Yanagihara K, Miyazaki Y, Mukae H: Pulmonary coccidioidomycosis complicated by nontuberculous mycobacterial pulmonary diseases with a literature review.. *Jpn J Infect Dis* : 2023.doi: 10.7883/yoken.JJID.2023.073. (IF: 2.541) \*
- 43 . Fujikura Y, Somekawa K, Manabe T, Horita N, Takahashi H, Higa F, Yatera K, Miyashita N, Imamura Y, Iwanaga N, Mukae H, Kawana A: Aetiological agents of adult community-acquired pneumonia in Japan: systematic review and meta-analysis of published data. *BMC Open Respir Res* 10(1): e001800,2023.doi: 10.1136/bmjjresp-2023-001800. (IF: -)
- 44 . Ogata R, Kido T, Takeda K, Nemoto K, Heima R, Takao M, Miyashita R, Ozasa M, Tokito T, Okuno D, Ito Y, Yura H, Koga T, Hashimoto K, Takemoto S, Takazono T, Ishimoto H, Sakamoto N, Fukuda K, Sasaki Y, Obase Y, Ishimatsu Y, Yatera K, Izumikawa K, Mukae H: Disseminated *Mycobacterium genavense* Infection Mimicking Sarcoidosis: A Case Report and Review of Literature on Japanese Patients. *Microorganisms* 11(9): 2145,2023.doi: 10.3390/microorganisms11092145.. (IF: 4.8) \*
- 45 . Tashiro M, Namie H, Ito Y, Takazono T, Kakeya H, Miyazaki Y, Mukae H, Mikamo H, Tomoo F, Shibuya K, Izumikawa K: Prognostic association of Liposomal Amphotericin B doses above 5 mg/kg in Mucormycosis: A nationwide epidemiologic and treatment analysis in Japan. *Open Forum Infect Dis* 10(10): ofad480,2023.doi: 10.1093/ofid/ofad480. (IF: -)
- 46 . Mine K, Sakamoto N, Ozasa M, Tsutsui S, Miyashita R, Tokito T, Okuno D, Yura H, Kido T, Ishimoto H, Takemoto S, Takazono T, Obase Y, Ishimatsu Y, Fukuoka J, Mukae H: Pulmonary Langerhans cell histiocytosis diagnosed using transbronchial lung cryobiopsy: A case report. *Respir Med Case Rep* 46: 10928,2023.doi: 10.1016/j.rmc.2023.101928. (IF: 1.1) \*
- 47 . Ashizawa N, Takazono T, Ito Y, Nakada N, Hirayama T, Takeda K, Ide S, Iwanaga N, Tashiro M, Hosogaya N, Yanagihara K, Mukae H, Izumikawa K: Antifungal susceptibility profiles of *Cryptococcus neoformans* strains clinically isolated from non-HIV-infected patients in Nagasaki, Japan. *Med Mycol* 61(10): myad100,2023.doi: 10.1093/mmy/myad100.. (IF: 2.9) \*
- 48 . Yamaguchi K, Kitamura M, Takazono T, Hashiguchi J, Funakoshi S, Mukae H, Nishino T: Prognoses of patients undergoing hemodialysis administered 23-valent pneumococcal polysaccharide versus 13-valent pneumococcal protein conjugate vaccines. *Med Mycol* 29(12): 1126-1131,2023.doi: 10.1016/j.jiac.2023.08.010. (IF: 2.9) \*
- 49 . Torigoe K, Yoshida Y, Sakamoto R, Abe S, Muta K, Arai H, Mukae H, Nishino T: Improvement in tubulointerstitial nephritis with glucocorticoid therapy in an anorexia nervosa patient. *J Med Cases* 14(9-10): 244-249,2023.-. (IF: -)

- 50 . Miyazaki T, Fukushima K, Hashiguchi K, Ide S, Kobayashi T, Sawai T, Yatera K, Kohno Y, Fukuda Y, Futsuki Y, Matsubara Y, Koga H, Mihara T, Sasaki E, Ashizawa N, Hirayama T, Takazono T, Yamamoto K, Immamura Y, Kaku N, Kosai K, Morinaga Y, Yanagihara K, Mukae H: A high  $\alpha$ 1-antitrypsin/interleukin-10 ratio predicts bacterial pneumonia in adults with community-acquired pneumonia: a prospective cohort study. *Pneumonia* 15(1): 16,2023.doi: 10.1186/s41479-023-00118-4. (IF: 6.8) \*
- 51 . Ota K, Kodama H, Kawamoto Y, Sasaki D, Mitsumoto-Kaseda F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Izumikawa K, Mukae H, Tun MMN, Morita K, Yanagihara K: The evaluation of a rapid microfluidic immunofluorescence antigen test in detecting the infectiousness of COVID-19 patients. *BMC Infect Dis* 23(1): 823,2023.doi: 10.1186/s12879-023-08821-9. (IF: 3.7) \*
- 52 . Matama G, Okamoto M, Fujimoto K, Johkoh T, Tominaga M, Mukae H, Sakamoto N, Komiya K, Umeki K, Komatsu M, Shimizu Y, Takahashi K, Tokisawa S, Zaizen Y, Matsuo N, Nouno T, Kaieda S, Ida H, Izuohara K, Hoshino T: Periostin Is a Biomarker of Rheumatoid Arthritis-Associated Interstitial Lung Disease. *J Clin Med* 12(22): 7100,2023.doi: 10.3390/jcm12227100. (IF: 3.9) \*
- 53 . Tanaka Y, Kido T, Sakamoto N, Hara A, Kato T, Miyashita R, Ozasa M, Tokito T, Okuno D, Takeda K, Yura H, Takemoto S, Takazono T, Ishimoto H, Obase Y, Ishimatsu Y, Miyazaki Y, Mukae H: Lung Involvement in Adult T-Cell Lymphoma Diagnosed Using Bronchoscopic Cryobiopsy: A Case Report and Review of the Literature. *Medicina* 59(11): 2015,2023.doi: 0.3390/medicina59112015.. (IF: 2.9) \*
- 54 . Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, Maeno T, Minato K, Tomono H, Ogawara D, Mukae H, Miura Y, Shiono A, Mouri A, Kagamu H, Kaira K: Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. *Sci Rep* 13(1): 2023.doi: 10.1038/s41598-023-48210-5.. (IF: 4.6) \*
- 55 . Hayashi F, Akagi K, Taniguchi H, Matsutake T, Kawahara H, Sekine I, Gyotoku H, Takemoto S, Soda H, Ashizawa K, Mukae H: TIM-3 expression induces resistance to PD-L1 inhibitor in G-CSF-producing lung spindle cell carcinoma; A case report. *Thorac Cancer* 14(36): 3501-3560,2023.doi: 10.1111/1759-7714.15149. (IF: 2.9) \*
- 56 . Okamoto M, Fujimoto K, Johkoh T, Kawaguchi A, Mukae H, Sakamoto N, Ogura T, Ikeda S, Kondoh Y, Yamano Y, Komiya K, Umeki K, Nishikiori H, Tanino Y, Tsuda T, Arai N, Komatsu M, Sakamoto S, Yatera K, Inoue Y, Miyazaki Y, Hashimoto S, Shimizu Y, Hozumi H, Ohnishi H, Handa T, Hattori N, Kishaba T, Kato M, Inomata M, Ishii H, Hamada N, Konno S, Zaizen Y, Azuma A, Suda T, Izuohara K, Hoshino T: A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib. *Sci Rep* 13(1): 22977,2023.doi: 10.1038/s41598-023-49180-4. (IF: 4.6) \*
- 57 . Akagi K , Fukushima K, Miyashita R , Kondo A, Kaneko Y, Ehara N, Yoshida S, Taniguchi H, Yamaguchi H, Mukae H, Sano I, Taniguchi H, Shigematsu K: Long-term survival after chemotherapy and salvage lobectomy for multiple station N2 stage IIIA non-small cell lung cancer: A case report. *ACTA MEDICA NAGASAKIENSIA* 67(1): 31-36,2023.-. (IF: -)
- 58 . Ishimoto H, Sakamoto N, Kido T, Ozasa M, Tsutsui S, Mori M, Setoguchi D, Takemoto S, Obase Y, Ishimatsu Y, Tomonaga C, Matsumoto K, Morisaki S, Miura K, Mukae H: Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature. *BMC Pulm Med* 23 23(1): 289,2023.doi: 10.1186/s12890-023-02569-3. (IF: 3.7) \*
- 59 . Tagawa R , Soda H, Dotsu Y, Senju H, Irifune S, Yoshida M, Nakashima S, Umemura A, Iwasaki K, Taniguchi H, Takemoto S, Fukuda Y, Mukae H: Hypertrophic osteoarthropathy associated with lung cancer: Possible links among hypoxia-inducible factor-1  $\alpha$ , vascular endothelial growth factor, and hypervascularization. *Thorac Cancer* 14(14): 1320-1324,2023.doi: 10.1111/1759-7714.14869.. (IF: 2.9) \*
- 60 . Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, Ono S, Umeyama Y, Shimada M, Gyotoku H, Takemoto S, Hisamatsu Y, Morinaga R, Tagawa R, Ogata R, Dotsu Y, Senju H, Soda H, Nakatomi K, Hayashi F, Sugasaki N, Kinoshita A, Mukae H: Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study. *Thorac Cancer* 14(28): 2890-2894,2023.doi: 10.1111/1759-7714.15097. (IF: 2.9) \*
- 61 . Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M: Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. *Adv Clin Chem* 112: 155-204,2023.doi: 10.1016/bs.acc.2022.09.004.. (IF: 5.394) \*

- 62 . Tanimura K, Uchino J, Kimura H, Hiranuma O, Chihara Y, Tanzawa S, Takumi C, Kita T, Inoue K, Minato K, Takemoto S, Nakao A, Yoshimura K, Takayama K: Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial. *Oncologist* 28(6): 551-e454,2023.doi: 10.1093/oncolo/oyad013.. (IF: 5.837) \*
- 63 . Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H , Yamamoto N, Nakagawa K : Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L. *Cancer Med* 12(23): 21097-21110,2023.doi: 10.1002/cam4.6668.. (IF: 4.711) \*
- 64 . Okuma Y, Nomura S, Ninomiya K, Gyotoku H, Murakami S, Kogure Y, Harada D, Okishio K, Okamoto H, Goto Y: Continuation of osimertinib in EGFR-mutant non-small-cell lung cancer patients bearing CNS metastasis (EPONA study). *Future Oncol* 19(22): 1515-1521,2023.doi: 10.2217/fon-2022-1128. (IF: 3.3) \*
- 65 . Akihiro Y, Tadaaki Y, Masakuni S, Hisanori U, Keiko T, Yusuke O, Akito F, Satoshi W, Naoya N, Takayuki T, Yusuke C, Shinnosuke T, Taishi H, Osamu H, Yukina S, Takehito S, Akihiro N, Yasuhiro G, Shinsuke S, Kei K, Kenji M, Yuki K, Kenichi S, Tetsuya M, Seiji Y, Hirotsugu K, Toshiaki T, Koichi T: High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib. *Cancer Sci* 114(2): 606-618,2023.doi: 10.1111/cas.15608.. (IF: 6.518) \*
- 66 . Noguchi R, Yoshimura A, Uchino J, Takeda T, Chihara Y, Ota T, Hiranuma O, Gyotoku H, Takayama K, Kondo T: Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations.. *Proteomes* 11(1): 2023.doi: 10.3390/proteomes11010006. (IF: 3.76) \*
- 67 . Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R: Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer. *Cancer Immunology, Immunotherapy* : 2023.doi: 10.1007/s00262-023-03528-x. (IF: 6.1) \*
- 68 . Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K: High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib. *Cancer Sci* . 114(2): 606-618,2023.doi: 10.1111/cas.15608.. (IF: 6.518) \*
- 69 . Fukahori S, Han J, Vera I, Lockey R, Kim K, Cho S: Elevated PAI-1 Levels Are Associated With Severe COVID-19. *J Allergy Clin Immunol* 151(2): AB190 ,2023.doi: 10.1016/j.jaci.2022.12.595. (IF: 14.29) \*
- 70 . Fukahori S, Cho S, Obase Y, Fukushima C, Mukae H, Lockey R: Differences In Therapeutic Efficacy Between Pressurized Metered-dose Inhaler And Dry Powder Inhaler For Asthma Patients With Small Airway Dysfunction. *J Allergy Clin Immunol* 151(2): AB337,2023.doi: 10.1016/j.jaci.2022.12.787. (IF: 14.29) \*
- 71 . Han J, Moon A, Tabor M, Fukahori S, Lockey R, Cho S: Increased Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM 5) Production and Its Role in Human Nasal Polyps. *J Allergy Clin Immunol* 151(2): AB107,2023.doi: 10.1016/j.jaci.2022.12.341. (IF: 14.29) \*
- 72 . Iwanaga N, Devarajan P, Shenoy AT: Editorial: Adaptive Immunity to Respiratory Pathogens. *Front Immunol* 14: 1174178,2023.doi: 10.3389/fimmu.2023.1174178.. (IF: 8.787) \*
- 73 . Yamasue M, Komiya K, Kinjo T, Ito A, Yamaguchi T, Iwanaga N, Ishii M, Tateda K, Kawakami K: Rebound mortality rate of Legionella pneumonia in Japan.. *Respir Investig* : 2023.doi: 10.1016/j.resinv.2023.04.005. \*

## A-b

- 1 . Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M: Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. *Adv Clin Chem* 112: 155-204,2023.doi: 10.1016/bs.acc.2022.09.004. Epub 2022 Nov 17.. (IF: 6.303) \*
- 2 . Hosogaya N, Takazono T, Ota K, Kiya R, Shirai Y, Kawasaki R, Yano H, Morimoto S, Nakao R, Kanamaru Y, Yoshino Y, Ishikawa Y, Fukushima C, Yamamoto H, Izumikawa K, Yanagihara K, Mukae H: Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol. *Medicine (Baltimore)* 102(8): e33092,2023.doi: 10.1097/MD.00000000000033092. (IF: 1.817) \*
- 3 . Yotsuyanagi H, Ohmagari N, Doi Y, Imamura T, Sonoyama T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H: A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part). *Medicine (Baltimore)* 102(8): e33024,2023.doi: 10.1097/MD.00000000000033024. (IF: 1.817) \*
- 4 . Ota K, Murakami S, Ishihara K, Sasaki D, Usui T, Mitsumoto-Kaseda F, Sakamoto K, Kosai K, Hasegawa H, Takazono T, Furumoto A, Asoh N, Yoshimine H, Sawai T, Onizuka M, Makimoto N, Izumikawa K, Mukae H, Kohno S, Yanagihara K: Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history. *Vaccine X* 13: 100282,2023.doi: 10.1016/j.vacx. (IF: -)
- 5 . Sakamoto N, Okuno D, Tokito T, Yura H, Kido T, Ishimoto H, Tanaka Y, Mukae H: HSP47: A Therapeutic Target in Pulmonary Fibrosis. *Biomedicines* 11(9): 2387,2023.doi: 10.3390/biomedicines11092387. (IF: 4.7) \*
- 6 . Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, Ono S, Umeyama Y, Shimada M, Gyotoku H, Takemoto S, Hisamatsu Y, Morinaga R, Tagawa R, Ogata R, Dotsu Y, Senju H, Soda H, Nakatomi K, Hayashi F, Sugasaki N, Kinoshita A, Mukae H: Phase II study of IRInotecan treatment after combined chemo-immunotherapy for extensive-stage small-cell lung cancer: protocol of IRICO study. *Thorac Cancer* 14(28): 2890-2894,2023.doi: 10.1111/1759-7714.15097. (IF: 2.9) \*
- 7 . Ogata R, Soda H, Fukuda Y, Mukae H: Exploring the ethical complexities of do-not-attempt-resuscitation orders using the approach of advance care planning. *Acute Med Surg* 10(1): e903,2023.doi: . (IF: 1.6) \*
- 8 . Tashiro M, Takazono T, Izumikawa K: Invasive Malassezia Infections.. *Med Mycol J* 64(4): 79-83,2023.doi: 10.3314/mmj.23-003. (IF: 1) \*
- 9 . Hanada M, Tanaka T, Kozu R, Ishimatsu Y, Sakamoto N, Orchanian-Cheff A, Rozenberg D, Reid WD: The interplay of physical and cognitive function in rehabilitation of interstitial lung disease patients: a narrative review. *J Thorac Dis* 15(8): 4503-4521,2023.doi: 10.21037/jtd-23-209. (IF: 2.5) \*

## B 邦文

### B-a

- 1 . 迎 寛, 四柳 宏, 大曲貴夫, 土井洋平, 倭 正也, 枝植優子, 坂口弘樹, 今村拓未, 福士剛純, 市橋健樹, 上原健城: エンシトレルビル フマル酸によるCOVID-19 罹患後症状 (Long COVID) 抑制の可能性. *Precision Medicine* 6(4): 39-47, 2023.
- 2 . 福島光基, 森尾暁介, 泊 慎也, 須山尚史, 泉川欣一, 泉川卓也, 泉川公一, 迎 寛: 魚骨の誤嚥により閉塞性肺炎を呈し, 気管支鏡下に魚骨を除去した1例. *気管支学* 45(6): 413-418, 2023.
- 3 . 福島光基, 吉岡寿麻子, 澤井豊光, 松尾信子, 門田淳一, 迎 寛: ユーグレナグラシリスによる薬剤性肺障害が疑われた1例. *日本呼吸器学会誌* 12(5): 1-5, 2023.
- 4 . 竹森幸子, 細萱直希, 福重友理, 森本心平, 福島千鶴, 山本弘史: 医師主導治験における安全性情報確認業務の電子化による業務効率化についての検討. *日本臨床試験学会雑誌* 51(s1): s32-s37, 2023.
- 5 . 大城亮作, 井手昇太郎, 平岡知子, 土橋佳子, 麻生憲史, 川元康嗣, 小佐井康介, 柳原克紀, 古本朗嗣: 生化学的性状で誤同定され質量分析法および16S rRNA遺伝子配列で診断が確定した*Streptococcus iniae*菌血症の1例. *感染症学雑誌* 97(5): 185-190, 2023.

B-b

- 1 . 迎 寛, 武田和明, 高園貴弘: 肺抗酸菌症と慢性肺アスペルギルス症との関連. *Kekkaku* 98(7): 259-261, 2023.
- 2 . 迎 寛, 武田和明: COVID-19,2類相当から5類へ. *呼吸器内科* 44(6): 648-651, 2023.
- 3 . 高園貴弘、迎 寛: 新規抗菌薬LSFXの使い方. *日本臨牀* 81(5): 758-763, 2023.
- 4 . 伊藤裕也, 迎 寛: 細菌性肺炎 呼吸器画像診断. *呼吸器ジャーナル* 71(3): 304-311, 2023.
- 5 . 尾長谷 靖、迎 寛: 鎮咳薬と喀痰調整薬. *Allos ergon* 3(1): 1-7, 2023.
- 6 . 尾長谷 靖、深堀 範、入来 隼、永江由香、高園貴弘、竹本真之輔、坂本憲穂、福島千鶴、迎 寛: 乾性咳嗽への実践的アプローチ. *呼吸器内科* 44(1): 15-20, 2023.
- 7 . 尾長谷 靖、迎 寛: 高齢者喘息とACOにおける治療戦略. *日本喘息学会誌* 2(1): 58-62, 2023.
- 8 . 岩永直樹, 迎 寛: 嫌気性菌感染症の病態と治療戦略. *呼吸器ジャーナル* 71(4): 468-474, 2023.
- 9 . 岩永直樹, 迎 寛: 4.市中肺炎（非定型肺炎） I章 呼吸感染症. *呼吸器内科学レビュー* 2024-25 20(24): 2023.
- 10 . 中田奈々, 高園貴弘, 迎 寛: インフルエンザの治療—成人及び高齢者. *臨床と研究* 100(12): 1446-1551, 2023.
- 11 . 小佐井康介, 柳原克紀, 迎 寛: インフルエンザと新型コロナウイルス感染症（COVID-19）の同時診断検査キットの展望. *インフルエンザ* 24(4): 221-226, 2023.
- 12 . 岩永直樹, 迎 寛: COVID-19流行下におけるインフルエンザ診療. *徳島県臨床内科医会会報* 28: 45-48, 2023.
- 13 . 岩永直樹, 迎 寛: 成人肺炎診療ガイドラインの展望. *呼吸器疾患最新の治療* 2023-2024 : 69-73, 2023.
- 14 . 迎 寛: 感染症に強い国づくり 内閣感染症危機管理統括庁、国立健康危機管理研究機構への期待と課題. *公明* 213: 62-68, 2023.
- 15 . 伊藤裕也, 竹本真之輔, 高園貴弘, 坂本憲穂, 尾長谷 靖, 迎 寛: マルチプレックスPCR, 呼吸器内科 = Respiratory medicine. *呼吸器内科編集委員会* 編 43(3): 299-304, 2023.

B-c

- 1 . 迎 寛: ニューモシスチス肺炎. 今日の治療指針2023年版 : 219-220, 2023.
- 2 . 迎 寛: 新型コロナウイルス感染症（COVID-19）. 診療の手引き・第10.0版 : 2023.
- 3 . 岩永直樹, 迎 寛: 成人肺炎診療ガイドラインの展望. . *呼吸器疾患最新の治療* 2023-2024 : 69-73, 2023.
- 4 . 迎 寛: COVID-19長崎大学の挑戦. 新型コロナウイルスパンデミック記録集 2020.1-2021.9(第1波-第5波) : 107-109, 2023.
- 5 . 大城亮作, 井手昇太郎, 平岡知子, 土橋佳子, 麻生憲史, 川元康嗣, 小佐井康介, 柳原克紀, 古本朗嗣: 生化学的性状で誤同定され質量分析法および16S rRNA遺伝子配列で診断が確定した*Streptococcus iniae*菌血症の1例. *感染症学雑誌* 97(5): 185-190, 2023.
- 6 . 井手昇太郎、古本朗嗣: 2023年度外来感染対策向上加算に係るカンファレンスおよび訓練. *長崎市医師会報* 57(12): 26-32, 2023.
- 7 . 黒石奈保, 金津真一, 高園貴弘, 岡本晃直, 富田章裕, 山永成美, 劍持 敬, 江川裕人, 井上健斗, 金兼弘和, 谷口俊文, 奥健志, 菊地 勘, 四柳 宏: 免疫不全患者における COVID-19 疾病負担. *Therapeutic Research* 44(12): 881-897, 2023.

## 論文研究業績集計表

### 論文数一覧

	A-a	A-b	A-c	A-d	A-e	SCI	合計	B-a	B-b	B-c	B-d	B-e	合計	総計
2023	73	9	0	0	0	59	82	5	15	7	0	0	27	109

### 学会発表数一覧

	A-a シンポジウム	A-b 学会	A-b 学会	合計	B-a	B-b シンポジウム	B-b 学会	合計	総計
2023	0	0	6	6	2	7	62	71	77

### 論文総数に係る教員生産係数

	欧文論文総数 論文総数	教員生産係数 (欧文論文)	SCI 掲載論文数 欧文論文総数	教員生産係数 (SCI 掲載論文)
2023	0.752	6.308	0.720	4.538

### Impact Factor 値一覧

	Impact Factor	教員当たりのImpact Factor	論文当たりのImpact Factor
2023	321.337	24.718	5.446